10X GENOMICS Gross Profit vs. Cash Per Share

1KJ Stock  EUR 14.54  0.58  3.84%   
Based on 10X GENOMICS's profitability indicators, 10X GENOMICS DL may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess 10X GENOMICS's ability to earn profits and add value for shareholders.
For 10X GENOMICS profitability analysis, we use financial ratios and fundamental drivers that measure the ability of 10X GENOMICS to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well 10X GENOMICS DL utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between 10X GENOMICS's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of 10X GENOMICS DL over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X GENOMICS guide.
Please note, there is a significant difference between 10X GENOMICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X GENOMICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X GENOMICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

10X GENOMICS DL Cash Per Share vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining 10X GENOMICS's current stock value. Our valuation model uses many indicators to compare 10X GENOMICS value to that of its competitors to determine the firm's financial worth.
10X GENOMICS DL is number one stock in gross profit category among its peers. It also is number one stock in cash per share category among its peers . The ratio of Gross Profit to Cash Per Share for 10X GENOMICS DL is about  73,568,728 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the 10X GENOMICS's earnings, one of the primary drivers of an investment's value.

10X Cash Per Share vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

10X GENOMICS

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
416.4 M
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

10X GENOMICS

Cash Per Share

 = 

Total Cash

Average Shares

 = 
5.66 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

10X Cash Per Share Comparison

10X GENOMICS is currently under evaluation in cash per share category among its peers.

10X GENOMICS Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in 10X GENOMICS, profitability is also one of the essential criteria for including it into their portfolios because, without profit, 10X GENOMICS will eventually generate negative long term returns. The profitability progress is the general direction of 10X GENOMICS's change in net profit over the period of time. It can combine multiple indicators of 10X GENOMICS, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. 10X GENOMICS operates under Health Information Services classification in Germany and is traded on Frankfurt Stock Exchange. It employs 852 people.

10X Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on 10X GENOMICS. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of 10X GENOMICS position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the 10X GENOMICS's important profitability drivers and their relationship over time.

Use 10X GENOMICS in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if 10X GENOMICS position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in 10X GENOMICS will appreciate offsetting losses from the drop in the long position's value.

10X GENOMICS Pair Trading

10X GENOMICS DL Pair Trading Analysis

The ability to find closely correlated positions to 10X GENOMICS could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace 10X GENOMICS when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back 10X GENOMICS - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling 10X GENOMICS DL to buy it.
The correlation of 10X GENOMICS is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as 10X GENOMICS moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if 10X GENOMICS DL moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for 10X GENOMICS can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your 10X GENOMICS position

In addition to having 10X GENOMICS in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Beers Thematic Idea Now

Beers
Beers Theme
Companies involved in production and distribution of domestic and international beer. The Beers theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beers Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in 10X Stock

To fully project 10X GENOMICS's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of 10X GENOMICS DL at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include 10X GENOMICS's income statement, its balance sheet, and the statement of cash flows.
Potential 10X GENOMICS investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although 10X GENOMICS investors may work on each financial statement separately, they are all related. The changes in 10X GENOMICS's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on 10X GENOMICS's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.